Company intelligence / Profile preview
Pyros Pharmaceuticals
Parsippany, New Jersey, United Statespyrospharma.com ↗
- Ownership
- Private
- Employees
- ~40
- Development stage
- Commercial
01
Overview
Pyros Pharmaceuticals developed VIGAFYDE™ (vigabatrin) oral solution, the first and only ready-to-use formulation for infantile spasms. The product was FDA-approved on June 17, 2024, and became available to patients in September 2024. It is the first new product approved for this indication in over a decade and offers improved dosing convenience for caregivers.
- Therapeutic areas
- Neurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Pyros Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pyros Pharmaceuticals.